Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod

 
• By Alaric DeArment
Blueprint Medicines announced the approval of Ayvakit in indolent systemic mastocytosis • Source: Shutterstock

More from New Products

More from Scrip